Literature DB >> 19892756

High frequencies of diabetic micro- and macroangiopathies in patients with type 2 diabetes mellitus with decreased estimated glomerular filtration rate and normoalbuminuria.

Hiroyuki Ito1, Yuichiro Takeuchi, Hidenori Ishida, Shinichi Antoku, Mariko Abe, Mizuo Mifune, Michiko Togane.   

Abstract

BACKGROUND: The clinical characteristics of diabetic patients presenting with normoalbuminuria with decreased kidney functions were investigated.
METHODS: A cross-sectional study was performed in 1197 patients with type 2 diabetes mellitus. The estimated glomerular filtration rate (eGFR) was calculated using the formula recommended by the Japanese Society of Nephrology.
RESULTS: The groups with normoalbuminuria, microalbuminuria, macroalbuminuria and renal failure consisted of 696 (58%), 229 (19%), 196 (16%) and 76 (6%) subjects, respectively. The frequencies of all diabetic micro- and macroangiopathies increased with progression of diabetic nephropathy stage. However, in the groups with chronic kidney disease (CKD) stage 3+4 (60 > eGFR > or = 15 mL/min/1.73 m(2)), the frequencies of diabetic neuropathy and macroangiopathies were not different among the groups staged by urinary albumin excretion. In the normoalbuminuria group, 223 (32%) cases showed CKD stage 3+4. Diabetic neuropathy and macroangiopathies were significantly more frequent in the groups presenting with normoalbuminuria with CKD stage 3+4 than in those with CKD stage 1+2 (eGFR > or = 60 mL/min/1.73 m(2)). The patients' age, duration of diabetes mellitus and frequency of hypertension were significantly higher in the groups presenting with normoalbuminuria with CKD stage 3+4. After adjustment by age, grade of albuminuria or both, CKD stage 3+4 was an independent risk factor for some diabetic complications.
CONCLUSIONS: The combination of urinary albumin excretion and eGFR is useful for earlier detection of kidney and vascular damage in patients with diabetes mellitus. Evaluation of eGFR should be performed for all diabetic patients even if they show normoalbuminuria.

Entities:  

Mesh:

Year:  2009        PMID: 19892756     DOI: 10.1093/ndt/gfp579

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  15 in total

1.  The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial.

Authors:  Amy K Mottl; Nicholas Pajewski; Vivian Fonseca; Faramarz Ismail-Beigi; Emily Chew; Walter T Ambrosius; Craig Greven; Ulrich Schubart; John Buse
Journal:  J Diabetes Complications       Date:  2014-07-12       Impact factor: 2.852

2.  Comparison between Three Different Equations for the Estimation of Glomerular Filtration Rate in Omani Patients with Type 2 Diabetes Mellitus.

Authors:  Salima R S Al-Maqbali; Waad-Allah S Mula-Abed
Journal:  Sultan Qaboos Univ Med J       Date:  2014-04-07

Review 3.  The goal of blood pressure control for prevention of early diabetic microvascular complications.

Authors:  Mark E Williams
Journal:  Curr Diab Rep       Date:  2011-08       Impact factor: 4.810

4.  Assessment of the relationship between 25-hydroxyvitamin D and albuminuria in type 2 diabetes mellitus.

Authors:  Seyed Alireza Zomorodian; Maryam Shafiee; Zeinab Karimi; Fatemeh Masjedi; Amirhossein Roshanshad
Journal:  BMC Endocr Disord       Date:  2022-07-04       Impact factor: 3.263

5.  Normoalbuminuric diabetic kidney disease in the U.S. population.

Authors:  Amy K Mottl; Keun-Sang Kwon; Michael Mauer; Elizabeth J Mayer-Davis; Susan L Hogan; Abhijit V Kshirsagar
Journal:  J Diabetes Complications       Date:  2012-11-24       Impact factor: 2.852

Review 6.  Is the presence of microalbuminuria a relevant marker of kidney disease?

Authors:  Richard J Glassock
Journal:  Curr Hypertens Rep       Date:  2010-10       Impact factor: 5.369

7.  Hyperuricemia is independently associated with coronary heart disease and renal dysfunction in patients with type 2 diabetes mellitus.

Authors:  Hiroyuki Ito; Mariko Abe; Mizuo Mifune; Koshiro Oshikiri; Shinichi Antoku; Yuichiro Takeuchi; Michiko Togane
Journal:  PLoS One       Date:  2011-11-18       Impact factor: 3.240

Review 8.  Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability.

Authors:  Shinya Nishio; Mariko Abe; Hiroyuki Ito
Journal:  Diabetes Metab Syndr Obes       Date:  2015-03-18       Impact factor: 3.168

9.  Flow Mediated Dilatation Is Reduced with the Progressive Stages of Glomerular Filtration Rate and Albuminuria in Type 2 Diabetic Patients without Coronary Heart Disease.

Authors:  Hiroyuki Ito; Mina Nakashima; Kentaro Meguro; Haruki Furukawa; Hitomi Yamashita; Akifusa Takaki; Chizuko Yukawa; Takashi Omoto; Masahiro Shinozaki; Shinya Nishio; Mariko Abe; Shinichi Antoku; Mizuo Mifune; Michiko Togane
Journal:  J Diabetes Res       Date:  2015-04-29       Impact factor: 4.011

10.  The Prevalence of the Risk Factors for Atherosclerosis among Type 2 Diabetic Patients Is Greater in the Progressive Stages of Chronic Kidney Disease.

Authors:  Hiroyuki Ito; Shinichi Antoku; Masahide Furusho; Masahiro Shinozaki; Mariko Abe; Mizuo Mifune; Michiko Togane; Kiyoko Ito; Tsutomu Sanaka
Journal:  Nephron Extra       Date:  2013-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.